Cutanogen Appoints Richard Kagan, MD as Chief Medical Advisor NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Cutanogen Corporation, an orphan clinical-stage regenerative medicine wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc....

Amarantus Subsidiary Cutanogen Corporation Announces Patent Issuance in Hong Kong Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS Patent Issuance Opens Potential to genetically modify cells used to produce ESSPeer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....